Modulation of cisplatinum cytotoxicity by p53: Effect of p53-mediated apoptosis and DNA repair

Molecular Pharmacology

Volumn 56, Issue 5, 1999, Pages 966-972

  Fan, Jianguo ^a   Bertino, Joseph R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; PROTEIN BCL 2; PROTEIN P53; TETRACYCLINE;

APOPTOSIS; ARTICLE; CELL PROTECTION; CONTROLLED STUDY; DNA REPAIR; DRUG CYTOTOXICITY; DRUG SENSITIVITY; GENE CONTROL; GENE EXPRESSION; GENE INDUCTION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; REGULATORY MECHANISM;

EID: 0032749714     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.56.5.966     Document Type: Article

References (38)

1. Almasan A, Linke SP, Paulson TG, Huang LC and Wahl GM (1995) Genetic instability as a consequence of inappropriate entry into and progression through S-phase. Cancer Metastasis Rev 14:59-73.
2. Biard DS, Martin M, Rhun YL, Duthu A, Lefaix JL, May E and May P (1994) Concomitant p53 gene mutation and increased radiosensitivity in rat lung embryo epithelial cells during neoplastic development. Cancer Res 54:3361-3364.
3. Borsellino N, Belldegrun A and Bonavida B (1995) Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res 55:4633-4639.
4. Clarke AR, Purdie CA, Harrison DJ, Morris RG, Bird CC, Hooper ML and Wyllie AH (1993) Thymocyte apoptosis induced by p53-dependent and independent pathways. Nature (Lond) 362:849-852.
5. Cox LS and Lane DP (1995) Tumour suppressors, kinases and clamps: How p53 regulates the cell cycle in response to DNA damage. Bioessays 17:501-508.
6. Donaldson KL, Goolsby GL and Wahl AF (1994) Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int J Cancer 57:847-855.
7. el Rouby S, Thomas A, Costin D, Rosenberg CR, Potmesil M, Silber R and Newcomb, EW (1993) p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression. Blood 82:3452-3459.
8. Fan S, Smith ML, Rivet DJ, Duba D, Zhan Q, Kohn KW, Fornace AJ Jr and O'Connor PM (1995) Disruption of p53 function sensitizes breast cancer MCF-7 cells to cisplatin and pentoxifylline. Cancer Res 55:1649-1654.
9. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA (1994) Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Cancer Res 54:2287-2291.
10. Gjerset RA, Turla ST, Sobol RE, Scalise JJ, Mercola D, Collins H and Hopkins PJ (1995) Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 14:275-285.
11. Gossen M and Bujard H (1992) Tight control of gene expression in mammalian cells by tetracycline-responsive promoters. Proc Natl Acad Sci USA 89:5547-5551.
12. Hall PA, Kearsey JM, Coates PJ, Norman DG, Warbrick E and Cox LS (1985) Characterisation of the interaction between PCNA and Gadd45. Oncogene 10: 2427-2433.
13. Hawkins DS, Demers GW and Galloway DA (1996) Inactivation of p53 enhances sensitivity to multiple chemotherapeutic agents. Cancer Res 56:892-898.
14. Jung M, Notario V and Dritschilo A (1992) Mutations in the p53 gene in radiation-sensitive and -resistant human squamous carcinoma cells. Cancer Res 52:6390-6393.
15. Kern SE, Pietenpol JA, Thiagalingam S, Seymour A, Kinzler KW and Vogelstein B (1992) Oncogenic forms of p53 inhibit p53-regulated gene expression. Science (Wash DC) 256:827-830.
16. Kondo S, Barnett GH, Hara H, Morimura T and Takeuchi J (1995) MDM2 protein confers the resistance of a human glioblastoma cell line to cisplatin-induced apoptosis. Oncogene 10:2001-2006.
17. Lane DP (1992) Cancer. p53, guardian of the genome. Nature (Lond) 358:15-16.
18. Lee JM, Abrahamson JL and Bernstein A (1994) DNA damage, oncogenesis and the p53 tumour-suppressor gene. Mutat Res 307:573-581.
19. Levine AJ, Momand J and Finlay CA (1991) The p53 tumour suppressor gene. Nature (Lond) 351:453-456.
20. Li WW, Fan J, Hochhauser D, Banerjee D, Zielinski Z, Almasan A, Yin Y, Wahl GM and Bertino JR (1995) Lack of functional retinoblastoma protein mediates increased resistance to antimetabolites in human sarcoma cell lines. Proc Natl Acad Sci USA 92:10436-10440.
21. Liebermann DA, Hoffman B and Steinman RA (1995) Molecular controls of growth arrest and apoptosis: p53-Dependent and independent pathways. Oncogene 11: 199-210.
22. Merlo GR, Basolo F, Fiore L, Duboc L and Hynes NE (1995) p53-Dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. J Cell Biol 128:1185-1196.
23. Miyashita T and Reed JC (1993) Bcl-2 oncoprotein blocks chemotherapy-induced apoptosis in a human leukemia cell line. Blood 81:151-157.
24. Momand J, Zambetti GP, Olson DC, George D and Levine AJ (1992) The mdm-2 oncogene product forms a complex with the p53 protein and inhibits p53-mediated transactivation. Cell 69:1237-1245.
25. Noble JR, Willetts KE, Mercer WE and Reddel RR (1992) Effects of exogenous wild-type p53 on a human lung carcinoma cell line with endogenous wild-type p53. Exp Cell Res 203:297-304.
26. Pardo FS, Su M, Borek C, Preffer F, Dombkowski D, Gerweck L and Schmidt EV (1994) Transfection of rat embryo cells with mutant p53 increases the intrinsic radiation resistance. Radiat Res 140:180-185.
27. Reed JC (1995) Regulation of apoptosis by bcl-2 family proteins and its role in cancer and chemoresistance. Curr Opin Oncol 7:541-546.
28. Roberts JM, Koff A, Polyak K, Firpo E, Collins S, Ohtsubo M and Massague J (1994) Cyclins, Cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol 59:31-38.
29. Rotter V, Aloni-Grinstein R, Schwartz D, Elkind NB, Simons A, Wolkowicz R, Lavigne M, Beserman P, Kapon A and Goldfinger N (1994) Does wild-type p53 play a role in normal cell differentiation? Semin Cancer Biol 5:229-236.
30. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Kris M and Dmitrovsky E (1995) Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Cancer Res 55:5038-5042.
31. Sanchez Y and Elledge SJ (1995) Stopped for repairs. Bioessays 17:545-548.
32. Selvakumaran M, Lin HK, Miyashita T, Wang HG, Krajewski S, Reed JC, Hoffman B and Liebermann D (1994) Immediate early up-regulation of bax expression by p53 but not TGF beta 1: A paradigm for distinct apoptotic pathways. Oncogene 9:1791-1798.
33. Sharma S, Schwarte-Waldhoff I, Oberhuber H and Schafer R (1993) Functional interaction of wild-type and mutant p53 transfected into human tumor cell lines carrying activated ras genes. Cell Growth Differ 4:861-869.
34. Smith ML, Chen IT, Zhan Q, O'Connor PM and Fornace AJ Jr (1995) Involvement of the p53 tumor suppressor in repair of u.v.-type DNA damage. Oncogene 10:1053-1059.
35. Stamatatos L, Leventis R, Zuckermann MJ and Silvius JR (1988) Interactions of cationic lipid vesicles with negatively charged phospholipid vesicles and biological membranes. Biochemistry 27:3917-3925.
36. Sturzbecher HW, Donzelmann B, Henning W, Knippschild U and Buchhop S (1996) p53 is linked directly to homologous recombination processes via rad51/reca protein interaction. EMBO J 15:1992-2002.
37. Wahl AF, Donaldson KL, Fairchild C, Lee FY, Foster SA, Demere GW and Galloway DA (1996) Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosia. Nat Med 2:72-79.
38. Zhu YM, Bradbury DA and Russell NH (1994) Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. Br J Cancer 69:468-472.